Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 6c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $13.88 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2021 revenue of $40-50 million, versus the consensus of $45.6 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance